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Osteoarthritis is a highly prevalent joint disorder with no effective disease-modifying 
treatment. Animal studies demonstrate that increased TGFβ1 activation in the subchondral 
bone induces osteoarthritis, whereas inhibition of TGFβ1 prevents disease progression. 
However, the understanding of this mechanism in human subchondral bone is still limited. This 
study aims to investigate the role of TGFβ1 in human osteoarthritic subchondral bone at the 
tissue, cellular, and molecular level. Tibial plateaus were collected from 35 osteoarthritic 
patients undergoing total knee replacement surgery (15 males, aged 68 ± 10 years; and 20 
females, aged 71 ± 8 years). Subchondral bone tissue was sampled from regions with less and 
more degenerated cartilage (mild and severe groups). Tissue sections were stained with 
Safranin O Fast Green and graded using OARSI grading system. They were also stained with 
Haematoxylin and Eosin to quantify osteocyte and vascular density, and with Tartrate-
Resistant Acid Phosphatase for TRAP+ cells density. ELISA was then performed to determine 
TGFβ1 concentrations. Additionally, TGFβ1 and bone marker gene expressions were 
determined by RT-PCR technique. A significant increase in the OARSI score (p < 0.0001), 
osteocytes (p = 0.012), vascular (p = 0.003), TRAP+ osteoclasts ((p = 0.002) and total TRAP+ 
cells ((p = 0.006) density were observed in this study. The concentration of active TGFβ1 and 
RANK/OPG mRNA expression were also increased in the severe group (p = 0.031 and p < 
0.0001, respectively). Furthermore, OARSI scores revealed positive correlations with 
active/total TGFβ1 (r = 0.34, p = 0.006), total TRAP+ cell (r = 0.34, p = 0.005), TRAP+ 
osteoclast cell (r = 0.30, p = 0.014), osteocyte (r = 0.29, p = 0.018), and vascular (r = 0.36, p = 
0.003) density. Together, this study demonstrates increased in TGFβ1 activation is associated 




Osteoarthritis is a highly prevalent joint disorder that affects the entire structure of the joint, 
including articular cartilage and subchondral bone1, 2. It presents with pain, stiffness and 
structural deformation of the joint making it a leading cause of disability among elderly 
worldwide3, 4. Despite the known risk factors for osteoarthritis, such as genetics, aging, obesity 
and joint injury4, the underlying mechanism behind the development of osteoarthritis remains 
unknown, as a result, no effective disease-modifying treatment currently available for 
osteoarthritis. 
 
In recent years, increasing number of studies suggest that transforming growth factor (TGF)β1 
is implicated in the pathogenesis of osteoarthritis5, 6. TGFβ is a cytokine that belongs to the 
TGF superfamily. TGFβ exist in three different isoforms: TGFβ1, TGFβ2 and TGFβ37. 
Amongst them, TGFβ1 is the most abundant growth factor in the bone8. TGFβs mainly stored 
as a latent complex in the extracellular matrix9. Released of TGFβ1 from the bone matrix 
during osteoclastic activity transduces signal through type I and II receptor serine/threonine 
kinase and subsequently activating the phosphorylation of SMAD2/3 pathway10, 11. TGFβ 
signalling regulates cellular processes, including proliferation, differentiation, migration and 
apoptosis, as well as production and degradation of extracellular matrix12, 13. In healthy 
cartilage, TGFβ/SMAD2/3 signalling pathway is responsible for the maintenance of articular 
cartilage homeostasis. TGFβ signalling stimulates chondrogenesis and inhibits chondrocytes 
terminal differentiation14. However, inhibition of TGFβ signalling in a SMAD3 knockout mice 
model demonstrates a chondrocyte hypertrophic, thereby leading to the degeneration of 
cartilage14, 15. 
 
TGFβ1 also has a critical role in maintaining homeostasis of the bone. During subchondral 
bone remodelling, TGFβ1 acts as a coupling factor for bone resorption and formation16. An 
osteoclast precursor receptor activator of nuclear factor-kB ligand (RANKL) expressed by 
preosteoblast cells bind to its receptor, RANK, on the surface of osteoclast cells17. The 
interaction of RANKL/RANK enhances differentiation of osteoclast precursor and activation 
of mature osteoclast to dissolve bone mineral and degrade bone matrix18. Soluble receptor 
osteoprotegerin (OPG), which is also secreted by osteoblast cells, can block the action of 
RANKL by binding with RANK to suppress osteoclastic bone resorption and stimulate bone 
formation17. The expression of RANKL and OPG is regulated by TGFβ118, 19. Therefore, 
interruption in TGFβ1 signalling causes an imbalance in the RANKL/OPG ratio leading to 
abnormal bone metabolism and damaged subchondral bone20. 
 
Following injury in an acute cruciate ligament transection (ACLT) murine model, an increase 
in subchondral bone resorption is associated with increase active TGFβ1 expression in that 
region21. Elevated TGFβ1 activity through SMAD2/3 pathway stimulates the formation of 
bone marrow lesion as a sign of early osteoarthritis21. Bone cells exposed to a high level of 
active TGFβ1 induce clustering of nestin+ MSCs, which leads to the formation of bone marrow 
osteoid islets and accompanied by increase angiogenesis21. The expression of osterix+ 
osteoprogenitor, a marker for osteoprogenitor cells, also increases in the subchondral bone 
suggesting that nestin+ MSCs differentiate into osteoblast cells for the development of new 
bone cells21. These findings were consistent with recent studies in animal models of 
spontaneous osteoarthritis and Camurati-Engelmann disease (CED)22, 23. Furthermore, 
overexpression of active TGFβ1 in leads to the development of subchondral bone sclerosis and 
degeneration of cartilage in a transgenic mice21. However, inhibition of TGFβ1 activity using 
an inhibitor reduced uncoupled bone remodelling and inhibited aberrant angiogenesis in the 
subchondral bone, which results in improved quality of the bone21. Therefore, TGFβ1 may 
potentially emerge as a novel therapeutic target for osteoarthritis through inhibition. 
 
The role of TGFβ1 has been well established in animal models. However, due to the limitation 
in tissues samples obtained from human osteoarthritis are exclusively at the late stage of the 
disease makes the understanding of the mechanism and prediction of disease development a 
challenging task. Therefore, it is difficult to distinguish whether the role of TGFβ1 observed 
in the preclinical animal model of osteoarthritis is translatable to humans in order to find an 
effective treatment for human osteoarthritis. This study proposes, for the first time, the use of 
paired bone samples from mild and severe osteoarthritis regions of the same joint. 
 
The hypothesis of this study is increased activity of TGFβ1 in the subchondral bone is 
associated with the progression of osteoarthritis. To investigate this, the expression and 
activation of TGFβ1 were measured in the mild and severe stages of osteoarthritis. Changes in 
the tissue, cellular and gene expression involved in bone remodelling at the different stage of 
disease were also investigated. 
 
MATERIALS AND METHODS 
 
Human bone samples 
With the approval from the Royal Adelaide Hospital and The University of Adelaide Human 
Research Ethics Committees, fresh tibial plateau samples were obtained from 35 individuals 
presenting with late stage of osteoarthritis that were undergoing total knee replacement surgery. 
Written informed consent was obtained from patients. In the medial tibia compartment, 
subchondral bone tissues were extracted from the underlying regions of less and more 
degenerated cartilage (Fig. 1). These tissues were processed for ELISA, real-time PCR and 
histological examination. The characteristics of patients are indicated in Table 1.  
 
 
Figure 1 Gross image of a female osteoarthritic tibial plateau, age 67 years, showing regions 
with less and more degenerated cartilage in the medial compartment. 
 
Table 1 
Basic characteristics of patients 
 Male Female p-value  
Sample size (n) 15 20   
Age (years) 68 ± 10 71 ± 8 0.402  
Values presented as mean ± standard deviation. 
 
Histological staining and histomorphometry 
For histological evaluation, regions of the medial tibia with less and more degenerated cartilage 
were sectioned with a low-speed diamond wheel saw (Model 660, South Bay Technology) to 
produce 10cm by 10cm by 10cm cuboidal cartilage-bone tissue blocks. Blocks of tissue were 





10% EDTA for 5 to 11 weeks. After radiologic confirmation of bone decalcification, the 
samples were processed and embedded in paraffin, and 5μm of sections were cut using a 
microtome (Leica RM2235, Leica Biosystems). The sections were stained with Safranin O Fast 
Green, Haematoxylin and Eosin (H&E) and Tartrate-Resistant Acid Phosphatase (TRAP). All 
stained slide sections were scanned using the Nanozoomer Digital Pathology slide scanner 
(C13239-01, Hamamatsu Photonics, Japan) and viewed using the NanoZoomer Digital 
Pathology system (U12388-01, Hamamatsu Photonics, Japan). 
 
Safranin O Fast Green stain and osteoarthritis scoring 
Sections were hydrated with distilled water 3 times for 1 minute each, stained with fast green 
solution for 20 minutes, and differentiated with 2 quick dipped into 1% acetic acid. After that, 
the sections were stained with safranin O solution for 5 minutes, rehydrated with ethanol in 
increasing concentrations, 95% and 100%, and dehydrated with xylene twice. 
 
The stained sections were then used to assess the severity of degenerated cartilage using the 
Osteoarthritis Research Society International (OARSI) grading system by two assessors24. The 
OARSI grades ranged from 1 to 6.5, where 1 indicates intact cartilage and 6.5 indicates a total 
loss of cartilage with affected underlying subchondral bone (Fig. 2). 
 
 
Figure 2 Representative images of OARSI histological grades observed in human tibial 
osteoarthritis samples from grade 1 to 6. 
 
Haematoxylin and eosin (H&E) stain and histoquantitative analaysis for osteocyte lacunar and 
vascular density 
Sections were stained with haematoxylin for 10 minutes and washed with acetate buffer for 5 
seconds. Then they were dipped into 0.1% acid alcohol for 30 seconds and stained with eosin 
for 5 minutes. After that, the sections underwent the rehydration step with ethanol in increasing 
concentrations, 95% and 100% and dehydrated with xylene twice. 
 
The H&E sections were used to quantify osteocyte lacunar density in the trabecular bone and 
vascular density in the subchondral bone marrow. In osteocyte lacunar density quantification, 
three regions of interest within the trabecular bone surface from each section were captured 
using NanoZoomer under 20x magnification (Fig. 3A). The area of the trabecular bone surface 
and the number of osteocytes occupied and empty lacunae were calculated using ImageJ 
software. The average values were obtained from each specimen. Occupied lacunae were 
defined as the presence of osteocyte nuclei in the lacunae (Fig. 3B). The density of osteocyte 




Figure 3 H&E staining of osteocyte lacunar in the trabecular bone. (A) A region of interest of 
osteocyte lacunar at 20x magnification. Scale bar: 100μm; (B) Osteocyte lacunar at 80x 
magnification. Black arrows indicate osteocyte occupied lacunae and the blue arrows indicate 
empty lacunae. Scale bar: 25μm. 
 
In vascular density quantification, image of the sections was captured using NanoZoomer at 
1x magnification to enable measurement of the whole subchondral bone area. The number of 
thick-walled blood vessels present in the subchondral bone marrow was counted using 
NanoZoomer (Fig. 4A and 4B), and the area of the bone was measured using ImageJ. The 
vascular density was expressed as the number of blood vessels per unit area (mm2) of tissue. 
 
 
Figure 4 H&E staining of blood vessels in the subchondral bone marrow. (A) Blood vessels at 
10x magnification indicated by black squares. Scale bar: 250μm; (B) Blood vessels at 20x 
magnification. Scale bar: 100μm. 
 
Tartrate-Resistant Acid Phosphatase (TRAP) stain and TRAP+ cell quantification 
Sections were hydrated with distilled water for 2 minutes, incubated in HCL solution for 1 hour 
at 37°C, and washed with distilled water for 2 minutes. The sections were then stained in 
freshly prepared acid phosphatase solution for 1 hour at 37°C and washed with distilled water 
for 1 minute. After that, the sections were dipped 4 times in haematoxylin stain and washed 
again with distilled water for 1 minute. Then the sections were dipped 4 times in lithium 
carbonate stain, and washed with distilled water for 1 minute. The sections were then 
rehydrated with ethanol in increasing concentrations, 95% and 100% and dehydrated with 
xylene twice.  
 
The stained sections were imaged using NanoZoomer at 1x magnification and used to quantify 
TRAP+ cells in the trabecular bone. The number of TRAP+ osteoclast cells and the total number 
of TRAP+ cells that comprised both TRAP+ osteoclasts and TRAP+ osteocyte cells were 
counted by two assessors. The area of the trabecular bone was measured using Bone J program 
in ImageJ. 
 
Enzyme-linked immunosorbent assay (ELISA) 
Subchondral bone tissues extracted from the samples were crushed in PEB solution and spin 
in a centrifuge at 13000g for 15 minutes. Bone tissue homogenates obtained were used to 
determine the concentration of active and total TGFβ1 by human TGFβ1 Quantikine ELISA 
kit (Cat. No: DB100B, R&D Systems, USA) following the manufacturer’s instructions. The 
total TGFβ1 was activated by adding 20µl of 1 N HCl into 100µl of the homogenate, incubated 
for 10 minutes at room temperature and neutralised by adding 20µl of 1.2 N NaOH. A total of 
50µl homogenate was added into the wells on ELISA plate and incubated for 2 hours. Then the 
wells were washed 4 times with 400µl wash buffer using microplate washer. After that, 100µl 
of TGFβ1 conjugate was added to each well and incubated for 2 hours at room temperature. 
Then the wells were washed again for 4 times, added with 100µl of substrate solution and 
incubated for 30 minutes with a cover protected from the light. Then 100µl stop solution were 
added to each well. The absorbance value of the samples was recorded using a microplate 
reader at a wavelength of 450nm. 
 
Reverse transcription polymerase chain reaction (RT-PCR) 
Subchondral bones extracted from human tibial plateaus were washed with PBS solution to 
remove blood and fat cells. Bone was crushed using approximately 20ml of liquid nitrogen and 
placed into 1ml of cold Trizol (Thermo Fisher Scientific). Specifically, samples were added 
with 0.2ml of chloroform and centrifuge for 20 minutes at 12000rcf at 4ºC. RNA was 
precipitated from the samples with 0.5ml of isopropanol and stored at -20ºC overnight. Then 
the RNA precipitates were washed 3 times in 75% ethanol. The yield and purity of the RNA 
were tested using Nanodrop One Microvolume Spectrophotometer (Thermo Fisher Scientific) 
and then they were stored in -80ºC until use. RNA was reverse transcribed using SuperscriptTM 
IV Reverse Transcriptase (Thermo Fisher Scientific). RT-PCR quantification of TGFβ1, 
SMAD3, TRAP, RANKL, OPG, DMP1, ALP, OCN and COL1 was performed in triplicate for 
each specimen using SYBR Green Mastermix (Cat. No: 330513, Qiagen, USA). 18S rRNA 
was considered as an internal control of the other mRNAs. Data were normalised using the 
2!(∆$%) method for analysis25. ∆Ct = Cttarget gene – Ct18S. Primer sequences are listed in Table 2. 
 
Table 2 
List of genes and primer sequences used for RT-PCR 
Gene Primer sequence (5’ – 3’) 
18S F – GCG TTG ATT AAG TCC CTG CC  
 R – CAC CTA AGG AAA CCT TGT TAC GAC 
TGF-β1 F – GAC ACC AAC TAT TGC TTC AG  
 R – AGA AGT TGG CAT GGT AGC CC 
SMAD3 F – TTC AAC AAC CAG GAG TTC GC 
 R – TAC TGG TCA CAG TAT GTC TC 
Table 2 (continued) 
TRAP F – GTG CAG ACT TCA TCC TGT CTC TA 
 R – AAT ACG TCC TCA AAG GTC TCC 
RANKL F – TCA GCC TTT TGC TCA TCT CAC TAT 
 R – CCA CCC CCG ATC ATG GT 
OPG F – GTC CAC AAG AAC AGA CTT TCC AG  
 R – CTG TTT TCA CAG AGG TCA ATA TCT T 
OCN F – TGA GAG CCC TCA CAC TCC TC 
 R – ACC TTT GCT GGA CTC TGC AC 
DMP1 F – GAT CAG CAT CCT GCT CAT GTT 
 R – AGC CAA ATG ACC CTT CCA TTC 
ALP F – TGC TCC CAC GCG CTT GTG CCT GGA 
 R – CTG GCA CTA AGG AGT TAG TAA G 
COL1 F – AGG CCT CCA ACG AGA TCG AGA TCC G 
 R – TAC AGG AAG CAG ACA GGG CCA ACG TCG 
 
Statistical analysis 
Shapiro-Wilk test was performed to assess the distribution of data. Comparisons between 
groups were evaluated using paired t-test for parametric data or Wilcoxon signed-rank test for 
non-parametric data, followed by Spearman rank to test for correlation. These analyses were 
performed using GraphPad Prism Software (GraphPad Prism, San Diego, CA, USA). 
Parametric data are presented as mean ± standard deviation (SD), and non-parametric data as 




Elevated TGFβ1 activation with increasing severity of osteoarthritis 
To determine the expression of TGFβ1 in osteoarthritis progression, subchondral bone tissues 
from the medial tibial plateau were extracted in regions with less and more degenerated 
cartilage categorised as mild and severe osteoarthritis groups (Fig. 5A and 5B). OARSI scores 
revealed the degeneration of cartilage in the severe group was significantly higher than in the 
mild group, indicating more progressive osteoarthritis (Fig. 5C). The expression of TGFβ1 
gene and concentration of total TGFβ1 protein in the subchondral bone was not different 
between mild and severe groups (Fig 5D and 5E). However, the concentration of active TGFβ1 
and the ratio of active/total TGFβ1 was significantly higher in the severe than in the mild group 
(Fig. 5F and 5G). 
 




















































Figure 5 Expression of TGFβ1 at the gene and protein level between mild and severe 
osteoarthritis. Safranin O Fast Green staining of sections from (A) mild and (B) severe cartilage 
degeneration in the same tibial plateau. Scale bar: 2.5mm. (C) OARSI scores; (D) TGFβ1 
relative mRNA expression; (E) Concentration of total TGFβ1; (F) Concentration of active 
TGFβ1; (G) Ratio of active/total TGFβ1 between groups. Each point represents an individual 
sample. Graphs show median ± interquartile range. * p < 0.05, **** p < 0.0001. 
 
Upregulated osteoclastic activity in severe osteoarthritis 
The activity of osteoclast cells in the trabecular bone was observed using TRAP staining (Fig. 
6A). The result shows that the number of TRAP+ osteoclast cells and total TRAP+ cell density 
was increased significantly in the severe relative to the mild group (Fig. 6B and 6C). 
 
         
Figure 6 TRAP activity in human osteoarthritic trabecular bone (A) TRAP staining of TRAP+ 



























































Total TRAP+ cell density
✱✱C
TRAP+ osteoclast cell density; (C) Total TRAP+ cell density between groups. Each point 
represents an individual sample. Graphs show median ± interquartile range. ** p < 0.01. 
 
High level of active TGFβ1 induces osteoblast differentiation and angiogenesis in the 
subchondral bone 
Next, the study examines the effect of elevated active TGFβ1 on osteocyte lacunar parameters 
in the trabecular bone. The result shows that there is a significant increase in osteocyte cells 
density in the severe compare to the mild group, suggesting an increase in osteoblast 
differentiation into osteocyte cells. However, the empty lacunar density was significantly 
decreased in the severe group (Table 3). 
 
Table 3 
Osteocyte and lacunar morphometric parameters in human osteoarthritis subchondral 
trabecular bone 
 Mild Severe p value 
Osteocyte density (#/mm2) 167.5 ± 41.2 204.8 ± 80.0 0.012 
Empty lacunar density (#/mm2) 108.8 ± 39.8 84.6 ± 28.8 0.01 
Total lacunar density (#/mm2) 276.4 ± 48.5 289.4 ± 95.5 0.457 
Empty/total lacunae (%) 39.2 ± 11.9 30.2 ± 9.6 0.002 
Values are presented as mean ± SD. 
 
This study also investigated the effect of TGFβ1 on the density of blood vessels in the 
subchondral bone marrow as an increase in angiogenesis is one of the hallmarks of 
osteoarthritis26. Vascular density in the subchondral bone marrow was significantly elevated in 
the severe compared to the mild group (Fig. 7). 
 
Figure 7 Quantitative analysis of vascular density in the human osteoarthritic subchondral 
bone marrow between the mild and severe groups. Each point represents an individual sample. 
Graph shows median ± interquartile range. ** p < 0.01. 
 
Association between TGFβ1 activity and bone parameters with increasing severity of 
osteoarthritis 
Correlation analysis of active/total TGFβ1 and bone parameters measured at the tissue level 
with OARSI score were all positively correlated in the combined cohort consisting of both mild 
and severe groups (Table 4). This indicates that active TGFβ1 and bone parameters are 
associated with increased progression of osteoarthritis. 
 
Table 4 
Correlations (r) with OARSI score 
 Mild Severe All 
Active/total TGFβ1 r = -0.03, p = 0.871 r = 0.28, p = 0.127 r = 0.34, p = 0.006 
Total TRAP+ cell density r = 0.18, p = 0.3 r = 0.15, p = 0.425 r = 0.34, p = 0.005 
TRAP+ osteoclast cell 
density 
r = -0.03, p = 0.854 r = 0.14, p = 0.453 r = 0.30, p = 0.014 
Osteocyte density r = 0.14, p = 0.428 r = 0.22, p = 0.209 r = 0.29, p = 0.018 














Differential gene expression for bone remodelling markers in human subchondral bone 
To investigate the molecular mechanism underlying the progression of osteoarthritis in human 
subchondral bone, the gene expressions of TGFβ1, SMAD3 and bone marker genes associated 
with bone resorption (TRAP, RANKL and OPG) and formation (DMP1, ALP, OCN and 
COL1) between the mild and severe osteoarthritis were examined. There was no significant 
difference in the mRNA expression of TGFβ1, SMAD3, TRAP, RANKL, OPG, DMP1, ALP, 
OCN and COL1 between the groups (data not shown). However, this study observed a 
significant increase in RANKL/OPG ratio in severe osteoarthritis, indicating an abnormal bone 
remodelling (Fig. 8). 
 
 
Figure 8 Bone remodelling marker RANKL/OPG gene expression ratio between mild and 
severe group. Each point represents an individual sample. Graph shows median ± interquartile 
range. * p < 0.05. 
 
Relationships between bone marker gene expressions 
The correlation between gene expressions was also examined to identify their relationship in 
co-regulating bone remodelling in the mild and severe osteoarthritis. The relationships between 
these genes are summarised in Table 5. TGFβ1, SMAD3 and DMP1 mRNA expressions were 


















expressions were also correlated positively with all bone marker genes except for OCN, a late 
osteoblast differentiation marker27. Both TGFβ1 and SMAD3 mRNA expression were 
positively correlated with OCN in mild osteoarthritis, while, no significant correlation 
observed between DMP1 and OCN in both groups. 
 
TRAP mRNA expression was positively correlated with RANKL, OPG, OCN and COL1 in 
the mild and severe osteoarthritis. However, an early osteoblast marker, ALP, was correlated 
positively with TRAP only in the severe group27. Further, ALP, RANKL and OPG mRNA 
expressions were correlated positively in the mild and severe osteoarthritis. 
 
Another early osteoblast differentiation marker, COL1, was positively correlated with 
RANKL, OCN and ALP in the mild osteoarthritis27. Meanwhile, COL1 and OCN mRNA 
expressions were correlated positively in both groups.   
 
Table 5 
Correlations between bone marker gene expression in mild and severe osteoarthritis 
 Mild Severe 
TGFβ1 vs RANKL r = 0.70, p < 0.0001 r = 0.71, p < 0.0001 
TGFβ1 vs OPG r = 0.87, p < 0.0001 r = 0.83, p < 0.0001 
TGFβ1 vs TRAP r = 0.86, p < 0.0001 r = 0.60, p = 0.001 
TGFβ1 vs OCN r = 0.55, p = 0.002 r = 0.23, p = 0.214 (ns) 
TGFβ1 vs COL1 r = 0.74, p < 0.0001 r = 0.51, p = 0.004 
TGFβ1 vs ALP r = 0.41, p = 0.037 r = 0.66, p = 0.001 
TGFβ1 vs SMAD3 r = 0.85, p < 0.0001 r = 0.71, p < 0.0001 
Table 5 (continued) 
TGFβ1 vs DMP1 r = 0.85, p < 0.0001 r = 0.75, p < 0.0001 
SMAD3 vs RANKL r = 0.71, p < 0.0001 r = 0.43, p = 0.031 
SMAD3 vs OPG r = 0.89, p < 0.0001 r = 0.68, p < 0.0001 
SMAD3 vs TRAP r = 0.80, p < 0.0001 r = 0.68, p = 0.0002 
SMAD3 vs OCN r = 0.43, p = 0.023 r = 0.14, p = 0.448 (ns) 
SMAD3 vs COL1 r = 0.73, p < 0.0001 r = 0.50, p = 0.007 
SMAD3 vs ALP r = 0.46, p = 0.025 r = 0.49, p = 0.038 
SMAD3 vs DMP1 r = 0.89, p < 0.0001 r = 0.76, p < 0.0001 
DMP1 vs RANKL r = 0.61, p = 0.0002 r = 0.47, p = 0.012 
DMP1 vs OPG r = 0.88, p < 0.0001 r = 0.68, p < 0.0001 
DMP1 vs TRAP r = 0.68, p < 0.0001 r = 0.58, p = 0.001 
DMP1 vs COL1 r = 0.78, p < 0.0001 r = 0.75, p < 0.0001 
DMP1 vs ALP r = 0.44, p = 0.021 r = 0.42, p = 0.049 
TRAP vs RANKL r = 0.71, p < 0.0001 r = 0.48, p = 0.015 
TRAP vs OPG r = 0.79, p < 0.0001 r = 0.73, p < 0.0001 
TRAP vs OCN r = 0.55, p = 0.001 r = 0.47, p = 0.012 
TRAP vs COL1 r = 0.73, p < 0.0001 r = 0.65, p = 0.0002 
TRAP vs ALP r = 0.29, p = 0.143 (ns) r = 0.56, p = 0.017 
COL1 vs RANKL r = 0.60, p = 0.0003 r = 0.37, p = 0.056 (ns) 
COL1 vs OPG r = 0.80, p < 0.0001 r = 0.52, p = 0.003 
COL1 vs OCN r = 0.48, p = 0.006 r = 0.30, p = 0.101 (ns) 
COL1 vs ALP r = 0.39, p = 0.047 r = 0.34, p = 0.126 (ns) 
 
Table 5 (continued) 
ALP vs RANKL r = 0.74, p < 0.0001 r = 0.86, p < 0.0001 
ALP vs OPG r = 0.64, p = 0.0005 r = 0.66, p = 0.002 
RANKL vs OPG r = 0.74, p < 0.0001 r = 0.61, p = 0.0007 




Findings of the present study demonstrated that severe osteoarthritic subchondral bone exhibits 
several outcomes of abnormal bone remodelling, including increased TGFβ1 activation, 
osteoclastic bone resorption, osteoblast differentiation and angiogenesis. These observations 
were associated with increasing severity of osteoarthritis. The expression of RANKL/OPG 
ratio was also elevated in the severe osteoarthritis, implying uncoupled bone remodelling. 
Therefore, this study highlights the role of TGFβ1 in the regulation of subchondral bone 
homeostasis and suggest that uncoupled bone remodelling enhanced the progression of 
osteoarthritis in the human subchondral bone. 
 
TGFβ1 has been widely known for its critical role in maintaining bone homeostasis by 
regulating osteoclast and osteoblast activity in the bone7. Similar to that observed in ACLT 
murine model, the activity of osteoclast and the level of active TGFβ1 were elevated in the 
severe osteoarthritis, indicating high concentrations of TGFβ1 were activated during 
osteoclastic bone resorption activity21. The aberrant release of active TGFβ1 disrupts the 
temporospatial relationship of bone resorption and formation resulting in further recruitment 
of nestin+ MSCs to the bone resorption site7, 16. The activity of MSCs to differentiate into 
osteoblast cells is often accompanied by angiogenesis. In the severe osteoarthritic subchondral 
bone marrow, there was an increase in the density of blood vessels. Previous study reported 
that TGFβ1 signalling in endothelial progenitor cells promote angiogenesis28. Therefore, 
increase angiogenesis in human subchondral bone marrow suggest that the hallmark of disease 
progression is a result of aberrant TGFβ1 activation. 
 
Osteocytes are terminally differentiated osteoblasts that become embedded in the bone matrix 
important for mineralisation of the bone29, 30. It forms dendritic processes that extend out of 
their cell bodies into the canaliculi forming lacuno-canalicular networks with the neighbouring 
osteocytes, osteoblast, osteoclast cells and vasculature29. Previous study revealed the 
importance of osteocytes in maintaining bone homeostasis by regulating the activity of 
osteoclast and osteoblast cells through their gap junctions present at the dendrites31, 32. 
Furthermore, osteocytes are also responsible for regulating perilacunar/canalicular remodeling 
to maintain their lacuno-canalicular networks, such as osteocyte communication, 
mechanosensation, nourishment and systemic mineral homeostasis29, 32, 33, 34, 35. TGFβ signaling 
in osteocyte regulates perilacunar/canalicular remodeling enzyme genes such as matrix 
metalloproteinases (MMPs) and Cathepsin K (Ctsk) that are expressed by the osteocyte cells33, 
36. Therefore, increase osteocyte apoptosis observed in the mild osteoarthritis affect osteocytes 
perilacunar/canalicular remodeling that result in reduced quality of the bone32. Consistent with 
prior reports, elevated osteocyte density was observed in the trabecular bone with increased 
severity of osteoarthritis37. This suggests that an increase in TGFβ1 activity in the severe 
osteoarthritis enhance osteoblast differentiation into osteocytes to increase regulation of 
perilacunar/canalicular remodelling and restore bone quality38. 
 
TGFβ1 signalling via SMAD3 pathway was shown to be involved in the progression of 
osteoarthritis. Since TGFβ1 regulates the expressions of SMAD3, TRAP, RANKL, OPG, 
DMP1, ALP, OCN and COL1, it is expected that TGFβ1, SMAD3 and the bone marker gene 
expressions are increased in the severe group18, 19, 32, 39,, 40. However, molecular analysis 
revealed that there were no differences in the gene expressions observed in this study. These 
could be due to genes are being expressed by cells other than osteoclast, osteoblast and 
osteocyte cells such as stromal cells41. Furthermore, factors such as RANKL and OPG has been 
shown to be involved in influencing bone remodelling process20. Although previous study 
demonstrated that RANKL and OPG are expressed by osteoblast cells in the osteoarthritic 
subchondral bone42, the ratio of RANKL/OPG in the mild and severe osteoarthritic 
subchondral bone remains to be determined. Interestingly, an increase in the expression of 
RANKL/OPG ratio was observed in the severe osteoarthritis. This is in line with studies in 
human temporomandibular joint and knee osteoarthritis which demonstrated that the serum 
ratio RANKL/OPG in the synovial fluid were increased with the severity of disease to induce 
osteoclastogenesis in the osteoarthritic joints43. Therefore, elevated RANKL/OPG ratio 
enhance more bone resorption activity occurred in the subchondral bone rather than bone 
formation, representing an imbalance bone remodelling in the human subchondral bone. 
 
The interrelationships between the expression of bone marker genes in the mild and severe 
groups were also investigated in this study. The positive correlation between both TGFβ1 and 
SMAD3 genes associated with TRAP, RANKL, OPG, DMP1, ALP and COL1 in mild and 
severe osteoarthritis indicates that the process of bone remodelling was regulated by 
TGFβ1/SMAD3 dependent pathway38, 44. This revealed that the role of TGFβ1/SMAD3 
signalling in the subchondral bone was altered from being a reparative to a damaging factor as 
disease progressed. Furthermore, the association of osteocyte marker, DMP1, with TGFβ1, 
SMAD3, TRAP, RANKL, OPG, ALP and COL1 in both groups may suggests that TGFβ1 
signalling via SMAD3 in osteocyte also regulate for bone remodelling process32. However, the 
expression of OCN was not associated with TGFβ1 and SMAD3 in the severe group, and with 
DMP1 in both groups. This could be due to the expression of OCN was regulated by the other 
cell subpopulations in the bone41. 
 
A proteolytic enzyme encoded by TRAP is highly expressed in osteoclast cells required for the 
degradation of organic bone matrix18. TRAP expression is associated with ALP in severe 
osteoarthritis, which was not observed in mild osteoarthritis. Both TRAP and ALP are critical 
for dephosphorylation of OPN45, 46. The role of OPN is to stimulate migration and attachment 
of osteoclast cells to the bone46. When OPN is dephosphorylated, osteoclast detached from the 
bone, migrate through the bone surface and allow bone formation at the resorption site. The 
correlation between TRAP and ALP suggest that these genes co-regulate suppression of 
inhibitory properties of OPN in severe osteoarthritis for subsequent bone formation47. 
Moreover, TRAP, RANKL and OPG are gene expressions associated with osteoclast 
differention42, 48. The correlation between these genes indicate that RANKL and OPG 
influences TRAP expression to regulate osteoclastic activity in both severity of osteoarthritis 
47, 49. 
 
The expression of COL1, ALP and OCN is associated with osteoblast differentiation. The 
positive correlation between these genes indicates that osteoprogenitor cells in mild 
osteoarthritis have the potential for cell differentiation into mature osteoblasts. However, the 
correlation between these genes was not significant in the severe osteoarthritis, showing that 
these genes might also be expressed by the stromal cells41. These could affect the activity of 
osteoprogenitor cells differentiation at the bone resorption site in the severe osteoarthritis, 
hence, affecting the coupled bone remodelling process. These findings revealed the complex 
interplay between the genes in the mild and severe osteoarthritis and illustrate a novel 
molecular mechanism by which the genes co-regulate in bone resorption and formation activity 
at the different severity of osteoarthritis. 
 
The strength of the current study is the use of human osteoarthritic osteochondral samples to 
investigate the cellular and molecular mechanisms of osteoarthritis progression rather than the 
use of animal models or cultured cells. However, this study presents some limitations, 
including the inability to obtain a healthy non-osteoarthritic sample to compare the 
observations due to ethical reasons. Presence of samples with extensively severe osteoarthritis 
where the cartilage in the samples was almost completely gone. Therefore, tissues obtained 
from mild regions in that sample were usually considered as a severe stage of osteoarthritis. 
Furthermore, the use of an entire bone cell populations from the tissue samples could also affect 
the outcomes of the study, especially in genetic analysis. This is because cells such as stromal 
cells found in the subchondral bone are also known to expressed TGFβ1 and the other bone 
marker genes. In the future studies, further analysis in tissue localisation of proteins such as 
pSMAD3, osterix+ and nestin+ MSCs, and CD31+ endothelial progenitor cells are required to 
determine the level of SMAD3 phosphorylation status, activity of osteoprogenitor osteoblast 
and endothelial cells differentiation. This would be valuable to evaluate the cellular mechanism 
of TGFβ1 through SMAD3 signalling as well as to identify its effect on osteogenesis and 
angiogenesis at the tissue level. 
 
In conclusion, the results of this study partially support the hypothesis where increased active 
TGFβ1 was observed with increased severity of osteoarthritis. The increase in TGFβ1 activity 
was associated with elevated osteoclastic activity, osteoblast differentiation and angiogenesis 
at the tissue and cellular level. The study also demonstrated that the expression of 
RANKL/OPG ratio was elevated at the molecular level. These changes observed between the 
different severity of osteoarthritis may provide an insight that inhibition of TGFβ1 activity at 
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